menu

Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers

4 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:
    Dustin Deming, MD
    ACI/Schwenn Family Associate Professor
    University of Wisconsin Carbone Cancer Center
    Madison, WI

    Consulting Fees: Array BioPharma, Bayer, Lilly, Pfizer, Promega

    Scott Kopetz, MD, PhD
    Deputy Chair, GI Medical Oncology
    Del and Dennis McCarthy Distinguished Professor
    MD Anderson Cancer Center
    Houston, TX 

    Consulting Fees: AstraZeneca/Medinfo, Boehringer Ingelheim, Boston Biomedical, EMD Serono, Genentech, Holy Stone, Lilly, Merck, Novartis

    Aparna R. Parikh, MD
    Assistant Professor of Medicine, Harvard Medical School
    Director of the MGH Cancer Center's Global Cancer Care Program
    Massachusetts General Hospital Cancer Center
    Boston, MA

    Consulting Fees: Biofidelity, Checkmate Pharmaceuticals, Eli Lilly, Guardant Health, Inivata, Natera, Pfizer, Roche/Genentech

    Research: Array, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Guardant Health, Mirati Therapeutics, Novartis Pharmaceuticals UK Ltd., Plexxikon, PMV Pharma, PureTech

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Colleen Resnick has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the key biomarkers for immunotherapy in patients with colorectal cancer (CRC)
    • Select optimal immunotherapy treatment based on biomarker testing results
    • Evaluate data on current and emerging therapies for patients with HER2+ CRC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, gastroenterologists, pathologists, oncology nurses, pharmacists, and other oncology healthcare providers involved in the treatment of patients with GI cancers globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until November 4, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-046-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Myers Squibb, Daiichi Sankyo, Inc., Genentech, a member of the Roche Group, Merck, and Seagen, Inc

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:
    Dustin Deming, MD
    ACI/Schwenn Family Associate Professor
    University of Wisconsin Carbone Cancer Center
    Madison, WI

    Consulting Fees: Array BioPharma, Bayer, Lilly, Pfizer, Promega

    Scott Kopetz, MD, PhD
    Deputy Chair, GI Medical Oncology
    Del and Dennis McCarthy Distinguished Professor
    MD Anderson Cancer Center
    Houston, TX 

    Consulting Fees: AstraZeneca/Medinfo, Boehringer Ingelheim, Boston Biomedical, EMD Serono, Genentech, Holy Stone, Lilly, Merck, Novartis

    Aparna R. Parikh, MD
    Assistant Professor of Medicine, Harvard Medical School
    Director of the MGH Cancer Center's Global Cancer Care Program
    Massachusetts General Hospital Cancer Center
    Boston, MA

    Consulting Fees: Biofidelity, Checkmate Pharmaceuticals, Eli Lilly, Guardant Health, Inivata, Natera, Pfizer, Roche/Genentech

    Research: Array, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Guardant Health, Mirati Therapeutics, Novartis Pharmaceuticals UK Ltd., Plexxikon, PMV Pharma, PureTech

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Colleen Resnick has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the key biomarkers for immunotherapy in patients with colorectal cancer (CRC)
    • Select optimal immunotherapy treatment based on biomarker testing results
    • Evaluate data on current and emerging therapies for patients with HER2+ CRC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, gastroenterologists, pathologists, oncology nurses, pharmacists, and other oncology healthcare providers involved in the treatment of patients with GI cancers globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until November 4, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-046-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Myers Squibb, Daiichi Sankyo, Inc., Genentech, a member of the Roche Group, Merck, and Seagen, Inc

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule6 Dec 2022